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We examined the absorption of phenolsulfonphthalein (PSP) and 
fluorescein isothiocyanate dextrans (FD-4, MW 4,400; FD-10, MW 
9,500; FD-40, MW 40,500) as model compounds through the small 
intestinal serosal surface.   After application to the rat 
small intestinal serosal surface using a cylindrical diffusion 
cell, each compound was absorbed at different rates.   The 
absorption ratios in 6 h after PSP, FD-4, FD-10 and FD-40 
application were calculated to be 89.2, 34.6, 14.9 and 2.1 % 
of dose, respectively.   Elimination profiles of PSP, FD-4 and 
FD-10 from the small intestinal serosal surface obeyed first-
order kinetics.   Moreover, we calculated the apparent 
permeability coefficient Papp for comparison to other organ 
surfaces.   The kidney had the highest absorption efficiency, 
as shown by having more than 1.5 times significantly higher 
Papp values of PSP, FD-4 and FD-10.   Similar to the other organ 
surfaces, a correlation was observed between the Papp of small 
intestine and the molecular weight of these hydrophilic 
compounds.   In addition, the small intestine is likely to 
contribute largely to hydrophilic compounds absorption from 
the peritoneal cavity, judging from absorption clearance CLa 





The peritoneal cavity is a useful space for intraperitoneal 
(i.p.) chemotherapy of cancer restricted to the peritoneal 
cavity, such as peritoneal carcinomatosis and ovarian cancer.   
The clarification of drug absorption characteristics from the 
peritoneal cavity would improve peritoneal chemotherapy.   
Intraperitoneally administered drugs are possibly absorbed 
from the peritoneum surrounding these peritoneal organs and 
the abdominal wall.   Previously, we reported on drug 
absorption from the liver surface (Nishida et al 1994), kidney 
surface (Nishida et al 2004), serosal stomach surface (Mukai 
et al 1999; Nakamura et al 1999) and serosal caecal surface 
(Nishida et al 2002) in rats utilizing the diffusion cell, and 
demonstrated the possibility that the peritoneal organ surface 
was greatly responsible for drug absorption from the 
peritoneal cavity.   Because the small intestine has the 
largest peritoneal area (Flessner 1996), its contribution to 
drug absorption from the peritoneal cavity might be 
considerable. 
 In this study, we have examined the absorption of model 
compounds with different molecular weights after their 
application to the rat small intestinal serosal surface, by 
utilizing a diffusion cell.   Phenolsulfonphthalein (PSP) and 
fluorescein isothiocyanate dextrans (FDs) were selected as 
model compounds because their absorption characteristics from 
other organ surfaces have been studied (Nishida et al 1995, 
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1996, 2002, 2004; Mukai et al 1999).   Furthermore, we compared 
the absorption rates among peritoneal organs using 
quantitative pharmacokinetic parameters. 
 
 
Materials and Methods 
Chemicals 
PSP (MW 354) was purchased from Nacalai Tesque, Inc. (Kyoto, 
Japan).   FDs (FD-4, MW 4,400; FD-10, MW 9,500; FD-40, MW 
40,500) were obtained from the Sigma Chemical Co. (St Louis, 
MD, U.S.A.).   All other chemicals were of reagent grade. 
 
Animal Experiments 
All animal experiments in the present study conformed to the 
Nagasaki University Guidelines for Animal Experimentation. 
 Male Wistar rats (260 - 290 g) were anaesthetized with 
sodium pentobarbitone (50 mg kg-1, i.p.) and the body 
temperatures were kept at 37 °C by a heat lamp during the 
experiments.   The left femoral artery was cannulated with a 
polyethylene tube (i.d. 0.5 mm, o.d. 0.8 mm, Dural Plastics, 
Dural, Australia).   An incision was made in the middle of the 
abdomen and the common bile duct was cannulated with a 
polyethylene tube (i.d. 0.28 mm, o.d. 0.61 mm, Becton 
Dickinson & Co., Parsippany, NJ, U.S.A.). 
 The drug solutions were prepared in isotonic phosphate 
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buffer (pH 7.4) to yield a concentration of 30 mg mL-1 and were 
administered as follows: 
 A cylindrical diffusion cell (i.d. 4 mm, area 0.13 cm2) was 
attached to the rat small intestinal serosal surface with the 
biocompatible glue Aron Alpha (Sankyo Co. Ltd, Tokyo, Japan).   
The drug solution (1 mg in 0.0334 mL) was added directly into 
the diffusion cell.   The top of the diffusion cell was sealed 
with aluminum foil to prevent evaporation. 
 Blood samples (200 μL) were collected at selected times 
after dosing from the heparinized cannula inserted into the 
femoral artery over a 6 h period, and were centrifuged at 
15,000 rpm for 5 min.   Bile samples were collected at 
appropriate time intervals for 6 h.   At 6 h after the 
application, urine was collected directly from the bladder 
with a syringe, and the drug solution remaining in the 
diffusion cell was withdrawn.   Certain experiments were 
carried out up to 0.5, 1, 2, 4 and 6 h after drug application. 
 
Analysis 
The concentrations of free PSP in the plasma, bile, urine and 
the solution remaining in the diffusion cell were determined 
spectrophotometrically at 560 nm after dilution with 1 M NaOH 
solution, by modifying the method previously described (Hart 
and Schanker 1966).   The total concentrations of free PSP and 
its metabolite were similarly measured after acid hydrolysis 
(1 M HCl at 100 °C for 30 min).   The concentration of the PSP 
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metabolite was estimated from the difference between these 
values. 
 The concentration of FDs as fluorescence was measured using 
a spectrophotofluorometer at excitation and emission 
wavelengths of 489 and 515 nm, respectively, by modifying the 
method previously described (Kurtzhals et al 1989). 
 Analytical validation information is follows.   The limits 
of quantification of PSP, FD-4, FD-10 and FD-40 were 0.010, 
0.0027, 0.0010 and 0.0038 µg mL-1, respectively.   The 
reproducibility of quantification was guaranteed by inter-day 
coefficient of variation (PSP, 1.1 %; FD-4, 0.9 %; FD-10, 
1.4 %; FD-40, 3.8 %) and intra-day coefficient of variation 
(PSP, 0.9 %; FD-4, 0.4 %; FD-10, 1.2 %; FD-40, 1.2 %).   The 
linearity of the calibration curve was guaranteed by 
correlation coefficient (R2 > 0.997).   In addition, the 




In all cases, post-hoc comparisons of the means of individual 
groups were performed using Tukey's test, following a one-way 
ANOVA.   A significance level of P < 0.05 denoted significance 
in all cases.   All values were expressed as the mean value ± 






Possibility of drug absorption from the rat small intestinal 
serosal surface 
Figure 1 shows the plasma concentration profiles of PSP, FD-4 
and FD-10 after application to the rat small intestinal 
serosal surface at a dose of 1 mg using the diffusion cell.   
After absorption from the small intestinal serosal surface, 
each model compound appeared in the plasma.   FD-4 and FD-10 
appeared in the plasma at significantly lower concentrations 
than PSP at each time point (Fig. 1). 
 
Recovery of model compounds in the diffusion cell, bile and 
urine 
Table 1 lists the recovery of model compounds in the diffusion 
cell, bile and urine 6 h after application to the small 
intestinal serosal surface at a dose of 1 mg.   The absorption 
ratio (% of dose) in 6 h of model compounds from the small 
intestinal serosal surface was calculated from the amount 
recovered from the diffusion cell at 6 h after application.   
The absorption ratio of PSP (89.2 %) was significantly larger 
than FD-4 (34.6 %), FD-10 (14.9 %) and FD-40 (2.1 %). 
 After application to the small intestinal serosal surface, 
model compounds were excreted into the bile and urine as 
listed in Table 1.   On the other hand, FD-4 and FD-10 absorbed 
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from the small intestinal serosal surface were mainly excreted 
into the urine, and their biliary excretion was significantly 
slight, compared to PSP. 
 
Elimination profiles of PSP, FD-4 and FD-10 from the small 
intestinal serosal surface 
We studied the time courses of PSP, FD-4 and FD-10 remaining 
in the diffusion cell.   The remaining amount (% of dose) of 
PSP was significantly smaller than FD-4 and FD-10 at each time 
point.   As illustrated in Fig. 2, semi-log plots of the time 
courses gave straight lines (correlation coefficient R2: 0.973 
for PSP, 0.988 for FD-4 and 0.988 for FD-10).   This suggests 
that drug absorption from the rat small intestinal serosal 
surface proceeds via a first-order process.   The absorption 
rate constants (ka) of PSP, FD-4 and FD-10 were calculated to 




Because the small intestine occupies about 40 % of the total 
peritoneal area in rats (Flessner 1996), we considered that 
its contribution to drug absorption from the peritoneal cavity 
was remarkable.   Flessner reported that absorption from the 
peritoneal cavity was dependent on the surface area exposed to 
the solution (Flessner 1996).   To obtain information about 
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drug absorption characteristics after i.p. administration, as 
a first step, we compared the drug absorption rates from 
several organ surfaces such as the liver (Nishida et al 1996), 
kidney (Nishida et al 2004), stomach (Mukai et al 1999) and 
caecum (Nishida et al 2002)), by employing the apparent 
permeability coefficient Papp.   Papp was calculated as the 





VkP ⋅=  (1) 
Where Va is the application volume of the drug solution, and 
Acell is the application area of the diffusion cell. 
 Table 2 summarizes the Papp of PSP, FD-4 and FD-10 after 
application to several organ surfaces.   The Papp values of PSP, 
FD-4 and FD-10 were not significantly changed for small 
intestine, liver, stomach and caecum.   While the kidney had 
the largest Papp values of PSP, FD-4 and FD-10, as shown by a 
more than 1.5 times significantly higher Papp value compared to 
other organ surfaces.   These results suggest that the kidney 
has the highest absorption efficiency for various molecular 
weight compounds among these organ surfaces. 
 Flessner measured the mass transfer rates of mannitol to the 
plasma from fluid in diffusion chambers affixed to the 
peritoneal surfaces of the rat caecum, liver, stomach and 
abdominal wall, and determined that the rates of mannitol 
transport were similar for all four organs (Flessner 1996).   
9 
The present result is in agreement with this previous study by 
Flessner (Flessner 1996) on the similar Papp of the rat caecum, 
liver and stomach.   However, we additionally indicated higher 
Papp for kidney surface of several model compounds with 
different molecular weights. 
 We have clarified that the absorption rates from several 
organ surfaces were dependent on the molecular weights of the 
model compounds (Nishida et al 1996, 2002, 2004; Mukai et al 
1999).   Then, we compared the absorption rates of model 
compounds with different molecular weights from the small 
intestinal serosal surfaces.   The following equation has been 
proposed with respect to drug absorption from the 









Where Pa represents the partition coefficient, and constants A 
and B are the correction factors to Pa and constants for 
diffusion, respectively. 
 Because each model compound has a high hydrophilicity 
(partition coefficient between n-octanol and water: < 0.08), Pa 
as a lipophilic index of each model compound is very small.   
This might enable us to assume that each Pa value is 
approximately identical.   Then, the right side of Eq. 2 can be 
transformed as a fixed number.   A linear relationship 
(correlation coefficient R2: 0.997) was observed between the 
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Papp values and the 1/ MW  values of PSP, FD-4, FD-10 and FD-40 
for the small intestinal serosal surface, similar to liver 
(Nishida et al 1996), kidney (Nishida et al 2004), stomach 
(Mukai et al 1999) and caecum (Nishida et al 2002).   This 
suggests that these hydrophilic model compounds were absorbed 
from the rat small intestinal serosal surfaces membranes via 
simple passive diffusion by the paracellular pathway, similar 
to other organ surfaces. 
 Table 2 lists the molecular weights when the Papp values are 
0 (MW limit), calculated by using the intercept of the x-axis 
(Papp = 0) on the relationship between the Papp and 1/ MW .   We 
considered that these values are equivalent to the limits of 
the molecular weights of drugs which can be absorbed from each 
organ surface in rats.   The limits of the molecular weights 
were different among the organ surfaces. 
 Furthermore, we calculated absorption clearance (CLa), 
according to Eq. 3, to estimate the contribution ratio for 
each organ to absorption from the peritoneal cavity. 
organappa APCL ⋅=  (3) 
CLa is the absorption clearance on the peritoneal organ itself 
from the peritoneal cavity.   Aorgan is the peritoneal surface 
area of an organ, which was previously measured (Flessner 
1991).   In this case, we assumed that each organ would 
contribute to drug absorption from the peritoneal cavity 
according to its proportion of peritoneal surface area in 
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contact with the peritoneal fluid.   As listed in Table 2, CLa 
values for the small intestine with every model compound were 
the significantly highest among these organ surfaces, probably 
by virtue of having the largest peritoneal area in the 
peritoneal cavity.   These results suggest that absorption from 
the small intestinal serosal surface contributes the most to 
hydrophilic drug absorption from the peritoneal cavity. 
 
 In conclusion, we clarified the absorption characteristics 
of model compounds with different molecular weights from the 
rat small intestinal serosal surface by the paracellular 
pathway.   These results should be useful to estimate overall 
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Table 1  Recovery (% of dose) of model compounds 6 h after 
application to the small intestinal serosal surface at a dose 
of 1 mg in rats 
 
 Compound n Diffusion cell (%) Bile (%) Urine (%) 
 
 PSP 6 10.8 61.9a 9.1a 
   ±1.3 ±4.0 ±3.5 
 
 FD-4 6 65.4 0.9 21.4 
   ±1.1 ±0.2 ±5.1 
 
 FD-10 6 85.1 0.4 12.2 
   ±0.8 ±0.1 ±0.8 
 
 FD-40 4 97.9 N.D.b N.D.b 
   ±0.4   
 
Each value is the mean ± s.e. of at least four experiments. 
a) The biliary and urinary recoveries of PSP represent the 
total amount of free PSP and its metabolite.   b) FD-40 could 






Table 2  Permeability coefficient (Papp) and absorption clearance (CLa) of model compounds after 
application to several organ surfaces at a dose of 1 mg in rats 
 
 Papp (µm min-1) a Aorgan c CLa(µL min-1) d
 –––––––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––– 
 Organ PSP FD-4 FD-10 MW limit b cm2 PSP FD-4 FD-10 
 
 Small intestine 15.9 (6) 2.62 (6) 1.18 (6) 44,800 186.3 (6) 296.2 (6) 48.8 (6) 22.0 (6) 
  ±0.8 ±0.10 ±0.07  ±7.5 ±15.4 ±1.9 ±1.3 
 
 Liver 10.9 (4) 2.56 (5) 1.51 (5) 71,200 71.7 (6) 77.9 (4) 18.4 (5) 10.8 (5) 
  ±1.4 ±0.17 ±0.18  ±1.9 ±9.8 ±1.2 ±1.3 
 
 Kidney 24.7 (4) 7.11 (4) 3.90 (4) 130,900 13.0 (6) 32.1 (4) 9.2 (4) 5.1 (4) 
  ±0.8 ±0.25 ±0.18  ±1.0 ±1.1 ±0.3 ±0.2 
 
 Stomach 12.3 (7) 2.47 (5) 0.76 (6) 23,700 16.3 (6) 20.1 (7) 4.0 (5) 1.2 (6) 
  ±0.9 ±0.21 ±0.21  ±0.7 ±1.5 ±0.3 ±0.3 
 
 Caecum 11.2 (8) 2.11 (5) 0.83 (5) 35,500 25.2 (6) 28.2 (8) 5.3 (5) 2.1 (5) 
  ±0.9 ±0.30 ±0.13  ±2.0 ±2.4 ±0.8 ±0.3 
 
Each value is the mean ± s.e. of at least four experiments.   The number of the experiments were 
indicated in the parenthesis. 
a) Papp was calculated by using ka according to equation 1.   ka values were obtained previously: 
liver (Nishida et al 1995, 1996), kidney (Nishida et al 2004), stomach (Mukai et al 1999), and 
caecum (Nishida et al 2002)).   b) MW limit was calculated by the intercept of the x-axis on the 
relationship between Papp and MW/1 .   c) Aorgan (peritoneal absorption area) of rats was reported 



















































Figure 1  Plasma concentration profiles of PSP (●), FD-4 (▲) 
and FD-10 (△) after application to the rat small intestinal 
serosal surface at a dose of 1 mg.   Each point represents the 
mean ± s.e. of six experiments. 
 
Figure 2  Semi-log plots of the PSP (●), FD-4 (▲) and FD-10 
(△) amount remaining in the diffusion cell after application 
to the rat small intestinal serosal surface at a dose of 1 mg.   
Each point represents the mean ± s.e. of four experiments.   
When no error bar is given, s.e. is smaller than the symbol 
used. 
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